SG11202000224SA - An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof - Google Patents
An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereofInfo
- Publication number
- SG11202000224SA SG11202000224SA SG11202000224SA SG11202000224SA SG11202000224SA SG 11202000224S A SG11202000224S A SG 11202000224SA SG 11202000224S A SG11202000224S A SG 11202000224SA SG 11202000224S A SG11202000224S A SG 11202000224SA SG 11202000224S A SG11202000224S A SG 11202000224SA
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- immunogenic composition
- improved stability
- enhanced immunogenicity
- reduced reactogenicity
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title 1
- 230000005847 immunogenicity Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721025513 | 2017-07-18 | ||
| PCT/IB2018/055180 WO2019016654A1 (en) | 2017-07-18 | 2018-07-13 | An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000224SA true SG11202000224SA (en) | 2020-02-27 |
Family
ID=63556364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000224SA SG11202000224SA (en) | 2017-07-18 | 2018-07-13 | An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11179453B2 (en) |
| EP (1) | EP3655024A1 (en) |
| JP (1) | JP7404226B2 (en) |
| CN (1) | CN111032078A (en) |
| AU (1) | AU2018302767A1 (en) |
| BR (1) | BR112020000999A2 (en) |
| CA (1) | CA3070039A1 (en) |
| CO (1) | CO2020001765A2 (en) |
| EA (1) | EA202090316A1 (en) |
| GE (1) | GEP20227386B (en) |
| JO (1) | JOP20180069B1 (en) |
| MX (1) | MX2020000441A (en) |
| PE (1) | PE20201443A1 (en) |
| PH (1) | PH12020500133A1 (en) |
| SG (1) | SG11202000224SA (en) |
| TW (1) | TWI786153B (en) |
| UY (1) | UY37811A (en) |
| WO (1) | WO2019016654A1 (en) |
| ZA (1) | ZA202000889B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1896065T2 (en) * | 2005-06-27 | 2014-12-31 | Glaxosmithkline Biologicals S.A. | Process for manufacturing vaccines |
| EP3045529B1 (en) | 2006-03-10 | 2020-07-29 | Institut Pasteur De Lille | Live attenuated bordetella strains as a single dose vaccine against whooping cough |
| ES2535412T3 (en) | 2009-04-28 | 2015-05-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vaccine for the prophylaxis or treatment of an airway pathology caused by an allergen |
| EP3697439A1 (en) * | 2017-10-18 | 2020-08-26 | Institut Pasteur de Lille | Bordetella strains expressing serotype 3 fimbriae |
| JOP20190242A1 (en) * | 2018-10-12 | 2020-04-12 | Serum Institute Of India Pvt Ltd | Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same |
| WO2020165920A1 (en) * | 2019-02-12 | 2020-08-20 | Biological E Limited | Multivalent vaccine composition |
| CN112138155B (en) * | 2019-06-28 | 2022-04-12 | 怡道生物科技(苏州)有限公司 | Compound adjuvant system and method for preparing adjuvant |
| JOP20200214A1 (en) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | Immunogenic compositions against enteric diseases and methods for its preparation thereof |
| EP3988288A1 (en) | 2020-10-23 | 2022-04-27 | Carl Zeiss Vision International GmbH | Method of manufacturing a spectacle lens |
| EP3988290A1 (en) | 2020-10-23 | 2022-04-27 | Carl Zeiss Vision International GmbH | Method for manufacturing a spectacle lens |
| EP3988289A1 (en) | 2020-10-23 | 2022-04-27 | Carl Zeiss Vision International GmbH | Method of manufacturing a spectacle lens |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0835663B1 (en) | 1992-05-23 | 2009-09-30 | GlaxoSmithKline Biologicals S.A. | Combined vaccines comprising Hepatitis B surface antigen and other antigens |
| PT1082965E (en) | 1995-06-23 | 2009-07-01 | Glaxosmithkline Biolog Sa | A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
| AU4707097A (en) | 1997-09-15 | 1999-04-05 | Pasteur Merieux Serums Et Vaccins | Multivalent vaccines |
| GB9806456D0 (en) | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
| EP1004314A1 (en) | 1998-11-26 | 2000-05-31 | Pasteur Merieux MSD | T.d. Polio booster vaccine for a primovaccinated or sensibilisated population |
| UA79735C2 (en) | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Purification of hbv antigens for use in vaccines |
| GB0313916D0 (en) * | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| GB0405787D0 (en) | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
| GB0616226D0 (en) | 2006-08-15 | 2006-09-27 | Novartis Ag | Processes |
| CA2662051A1 (en) * | 2006-09-07 | 2008-03-13 | Glaxosmithkline Biologicals S.A. | Vaccine |
| PE20100365A1 (en) * | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | NEW COMBINATION VACCINES WITH WHOLE CELL COUGH AND METHOD FOR THEIR PREPARATION |
| PE20100366A1 (en) | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | NOVEL COMPOSITIONS OF VACCINE WITH CELLULAR WHOOUS COUGH AS WELL AS THE METHOD FOR ITS ELABORATION |
| US10092640B2 (en) * | 2011-01-05 | 2018-10-09 | Bharat Biotech International Limited | Combination heptavalent vaccine |
| US20160193322A1 (en) * | 2013-08-05 | 2016-07-07 | Glaxosmithkline Biologicals S.A. | Combination immunogenic compositions |
| TN2018000063A1 (en) * | 2015-09-16 | 2019-07-08 | Lg Chemical Ltd | Combination vaccine composition for multiple-dosage. |
-
2018
- 2018-07-13 CN CN201880048015.1A patent/CN111032078A/en active Pending
- 2018-07-13 US US16/631,965 patent/US11179453B2/en active Active
- 2018-07-13 MX MX2020000441A patent/MX2020000441A/en unknown
- 2018-07-13 CA CA3070039A patent/CA3070039A1/en active Pending
- 2018-07-13 SG SG11202000224SA patent/SG11202000224SA/en unknown
- 2018-07-13 WO PCT/IB2018/055180 patent/WO2019016654A1/en unknown
- 2018-07-13 GE GEAP201815276A patent/GEP20227386B/en unknown
- 2018-07-13 EA EA202090316A patent/EA202090316A1/en unknown
- 2018-07-13 AU AU2018302767A patent/AU2018302767A1/en active Pending
- 2018-07-13 BR BR112020000999-7A patent/BR112020000999A2/en unknown
- 2018-07-13 JP JP2020502265A patent/JP7404226B2/en active Active
- 2018-07-13 EP EP18768937.7A patent/EP3655024A1/en active Pending
- 2018-07-13 PE PE2020000084A patent/PE20201443A1/en unknown
- 2018-07-17 JO JOP/2018/0069A patent/JOP20180069B1/en active
- 2018-07-17 UY UY0001037811A patent/UY37811A/en unknown
- 2018-07-17 TW TW107124600A patent/TWI786153B/en active
-
2020
- 2020-01-17 PH PH12020500133A patent/PH12020500133A1/en unknown
- 2020-02-11 ZA ZA2020/00889A patent/ZA202000889B/en unknown
- 2020-02-17 CO CONC2020/0001765A patent/CO2020001765A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3655024A1 (en) | 2020-05-27 |
| UY37811A (en) | 2019-01-02 |
| GEP20227386B (en) | 2022-06-10 |
| US20200206331A1 (en) | 2020-07-02 |
| WO2019016654A1 (en) | 2019-01-24 |
| CN111032078A (en) | 2020-04-17 |
| BR112020000999A2 (en) | 2020-07-14 |
| AU2018302767A1 (en) | 2020-03-05 |
| TW201919690A (en) | 2019-06-01 |
| JP7404226B2 (en) | 2023-12-25 |
| MX2020000441A (en) | 2020-08-17 |
| ZA202000889B (en) | 2021-06-30 |
| JOP20180069B1 (en) | 2022-09-15 |
| JP2020527571A (en) | 2020-09-10 |
| EA202090316A1 (en) | 2020-12-08 |
| PE20201443A1 (en) | 2020-12-10 |
| PH12020500133A1 (en) | 2021-02-08 |
| KR20200042470A (en) | 2020-04-23 |
| CO2020001765A2 (en) | 2020-05-29 |
| TWI786153B (en) | 2022-12-11 |
| JOP20180069A1 (en) | 2019-01-18 |
| US11179453B2 (en) | 2021-11-23 |
| CA3070039A1 (en) | 2019-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202000889B (en) | An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof | |
| HK1250136A1 (en) | Vaccine compositions having improved stability and immunogenicity | |
| ZA201807203B (en) | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof | |
| IL252915A0 (en) | Immunogenic compositions for use in pneumococcal vaccines | |
| PH12017502233A1 (en) | Formulations for neoplasia vaccines and methods of preparing thereof | |
| IL268168A (en) | Immunogenic compositions for use in pneumococcal vaccines | |
| EP3668541A4 (en) | Pneumococcal conjugate vaccine formulations | |
| EP3585803A4 (en) | Pneumococcal conjugate vaccine formulations | |
| SG11202003796XA (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
| SG11202001161YA (en) | Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3 | |
| SG11202004863QA (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
| ZA201608487B (en) | Dual adjuvant vaccine compositions, preparation and uses | |
| WO2016207853A3 (en) | Antigenically matched influenza vaccines | |
| GB201711635D0 (en) | Immunogenic composition | |
| GB201802339D0 (en) | Immunogenic composition | |
| ZA201706867B (en) | Bordetella pertussis immunogenic vaccine compositions | |
| GB201711637D0 (en) | Immunogenic composition | |
| EP3270897A4 (en) | Immunogenic compositions for use in vaccination against bordetella | |
| IL271603A (en) | Immunogenic compositions | |
| GB2570806B (en) | Immunogenic agent and associated compositions, uses and methods | |
| EP3580227A4 (en) | Alphavirus nsp mutants as vaccines | |
| GB201803692D0 (en) | Immunogenic composition | |
| EP3271023A4 (en) | Immunogenic compositions and vaccines for preventing or treating filarial disease | |
| GB201820010D0 (en) | Immunogenic composition | |
| GB201714183D0 (en) | Universally immunogenic formulations |